Northland Capmk Predicts Weaker Earnings for Sanuwave Health

Key Points

• Northland Capmk has revised its Q3 2025 EPS estimate for Sanuwave Health, lowering it from $0.08 to $0.03, while maintaining a "Strong-Buy" rating on the stock.
• The company's recent earnings report revealed a profit of $0.01 per share, exceeding analysts' expectations, with revenues of $10.16 million.
• As of recent trading, Sanuwave Health shares have seen a substantial decline of 21.6%, with a market cap of $274.33 million.

Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Research analysts at Northland Capmk dropped their Q3 2025 EPS estimates for shares of Sanuwave Health in a report issued on Tuesday, October 7th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.08. Northland Capmk currently has a "Strong-Buy" rating on the stock.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.10. The firm had revenue of $10.16 million during the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Sanuwave Health in a report on Saturday, September 27th. Wall Street Zen raised Sanuwave Health from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. Roth Capital set a $53.00 price objective on shares of Sanuwave Health and gave the company a "buy" rating in a research note on Tuesday. Finally, Northland Securities initiated coverage on shares of Sanuwave Health in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $54.00.

Sanuwave Health Trading Down 21.6%

Shares of SNWV opened at $32.01 on Wednesday. The company has a 50-day moving average of $37.78 and a two-hundred day moving average of $33.88. The stock has a market cap of $274.33 million, a P/E ratio of -3.88 and a beta of 1.33. Sanuwave Health has a 12-month low of $5.63 and a 12-month high of $46.58.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SNWV. Opaleye Management Inc. grew its holdings in Sanuwave Health by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 980,000 shares of the company's stock worth $32,203,000 after acquiring an additional 7,998 shares in the last quarter. Solas Capital Management LLC bought a new position in shares of Sanuwave Health in the 1st quarter worth about $20,658,000. AWM Investment Company Inc. acquired a new position in Sanuwave Health in the first quarter valued at approximately $18,153,000. Geode Capital Management LLC bought a new position in shares of Sanuwave Health during the second quarter valued at approximately $5,184,000. Finally, Stonebridge Wealth Management LLC acquired a new stake in Sanuwave Health in the second quarter worth $1,696,000. 42.53% of the stock is currently owned by institutional investors.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.